1. Home
  2. NOTV vs VXRT Comparison

NOTV vs VXRT Comparison

Compare NOTV & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NOTV
  • VXRT
  • Stock Information
  • Founded
  • NOTV 1974
  • VXRT N/A
  • Country
  • NOTV United States
  • VXRT United States
  • Employees
  • NOTV N/A
  • VXRT N/A
  • Industry
  • NOTV Biotechnology: Pharmaceutical Preparations
  • VXRT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NOTV Health Care
  • VXRT Health Care
  • Exchange
  • NOTV Nasdaq
  • VXRT Nasdaq
  • Market Cap
  • NOTV 137.5M
  • VXRT 119.0M
  • IPO Year
  • NOTV 1997
  • VXRT N/A
  • Fundamental
  • Price
  • NOTV $2.21
  • VXRT $0.41
  • Analyst Decision
  • NOTV Strong Buy
  • VXRT Strong Buy
  • Analyst Count
  • NOTV 3
  • VXRT 2
  • Target Price
  • NOTV $5.92
  • VXRT $3.00
  • AVG Volume (30 Days)
  • NOTV 552.5K
  • VXRT 1.7M
  • Earning Date
  • NOTV 05-09-2025
  • VXRT 03-20-2025
  • Dividend Yield
  • NOTV N/A
  • VXRT N/A
  • EPS Growth
  • NOTV N/A
  • VXRT N/A
  • EPS
  • NOTV N/A
  • VXRT N/A
  • Revenue
  • NOTV $475,114,000.00
  • VXRT $28,700,000.00
  • Revenue This Year
  • NOTV $6.37
  • VXRT N/A
  • Revenue Next Year
  • NOTV $5.74
  • VXRT $48.02
  • P/E Ratio
  • NOTV N/A
  • VXRT N/A
  • Revenue Growth
  • NOTV N/A
  • VXRT 288.94
  • 52 Week Low
  • NOTV $1.23
  • VXRT $0.39
  • 52 Week High
  • NOTV $11.20
  • VXRT $1.34
  • Technical
  • Relative Strength Index (RSI)
  • NOTV 35.56
  • VXRT 30.14
  • Support Level
  • NOTV $2.72
  • VXRT $0.49
  • Resistance Level
  • NOTV $3.35
  • VXRT $0.60
  • Average True Range (ATR)
  • NOTV 0.31
  • VXRT 0.05
  • MACD
  • NOTV -0.03
  • VXRT -0.01
  • Stochastic Oscillator
  • NOTV 16.79
  • VXRT 9.77

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

About VXRT Vaxart Inc

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Share on Social Networks: